Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced acceptance of long-term clinical data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” for presentation at Digestive Disease Week 2026 (May 2–5, 2026) in Chicago and virtually.
The abstract covers long-term outcomes for a transvascular radiofrequency nerve‑targeted ablation approach intended to reduce severe pain in pancreatic adenocarcinoma patients.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AMIX
On the day this news was published, AMIX declined 6.66%, reflecting a notable negative market reaction. Argus tracked a trough of -18.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $304K from the company's valuation, bringing the market cap to $4.27M at that time. Trading volume was elevated at 2.8x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMIX gained 3.57% while peers showed mixed moves: BMRA up 1.4%, HSCS down 7.41%, MOVE down 2.73%, HSDT down 0.95%. Momentum scanner also flagged PAVM down 3.75% and HSDT up 4.33%, reinforcing a stock-specific rather than broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Conference presentation | Positive | -2.3% | Announcement of long-term pancreatic cancer pain data presentation at ECIO 2026. |
| Apr 08 | Conference selection | Positive | +4.5% | Featured abstract and podium slot for long-term pain mitigation data at SIR 2026. |
| Mar 11 | Investor conference | Positive | +0.3% | CEO presentation and investor meetings at LSI USA ’26 medtech summit. |
| Mar 05 | Innovation competition | Positive | +2.2% | Selection for CRT 2026 Best Innovation Competition highlighting nerve-targeted technology. |
| Mar 04 | Top abstract award | Positive | +3.1% | Top Abstract and podium presentation on transvascular peripheral RF nerve neurolysis at CRT 2026. |
Conference and presentation news has generally produced modest, often positive price reactions, with one recent negative divergence.
Over the past few months, Autonomix has repeatedly showcased its transvascular RF-based nerve-targeted technology at major medical meetings. Events included Top Abstract and innovation selections at CRT 2026, investor-focused visibility at LSI USA ’26, and featured podium presentations at SIR 2026 and ECIO 2026. Price reactions to these announcements have mostly been mildly positive, though the ECIO 2026 presentation saw a -2.3% move. Today’s DDW 2026 abstract acceptance continues this pattern of conference-driven visibility around long-term pain mitigation data in pancreatic cancer.
Regulatory & Risk Context
An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant-related resale shares from a PIPE. Autonomix would not receive proceeds from resales but could receive up to $7.7 million in gross cash if the Common Warrants are exercised, and full exercise would significantly increase the share count, implying potential dilution for existing holders.
Market Pulse Summary
The stock moved -6.7% in the session following this news. A negative reaction despite abstract acceptance would fit the mixed history of conference-driven moves, including a recent -2.3% response to similar long-term data at ECIO 2026. While DDW 2026 adds scientific validation and visibility, investors also contend with substantial net losses and disclosed going-concern risks. The existing S-3 resale registration and warrant overhang, along with significant additional financing needs, could weigh on sentiment around otherwise positive clinical milestones.
Key Terms
pancreatic adenocarcinoma medical
denervation medical
transvascular medical
radiofrequency (rf) energy-based ablation medical
gastroenterology medical
hepatology medical
endoscopy medical
gastrointestinal medical
AI-generated analysis. Not financial advice.
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL and virtually.
Pancreatic adenocarcinoma is frequently associated with severe, debilitating pain that significantly impacts patient quality of life. The data to be presented highlights long-term outcomes associated with Autonomix’s transvascular radiofrequency (RF) energy-based ablation approach, which is designed to target and disrupt nerve signaling pathways responsible for pain transmission.
“This acceptance at DDW 2026 underscores our strategy of socializing and validating our data at preeminent conferences alongside world-renowned KOLs and clinical leaders,” said Dr. Robert Schwartz, Autonomix Co-Founder and Chief Medical Officer. “We are encouraged by the long-term findings and look forward to sharing these insights with the global gastroenterology and surgical community.”
Digestive Disease Week is one of the world’s premier gatherings for physicians, researchers, and industry leaders in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference provides a platform for cutting-edge research and advancements that shape the future of digestive healthcare. For more information, please visit the DDW 2026 conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
